CLOs on the Move

Cultiv8 Hemp Solutions

www.cultiv8hs.com

 
Cultiv8 Hemp Solutions, Inc. specializes in the growth and harvest of industrial hemp. We manufacture biodegradable paper and plastic alternatives, as well as biofuel, protien, and biomass.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

La Jolla Bioengineering Institute

La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.

Altea Therapeutics Corporation

Altea Therapeutics Corporation is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Kiniciti

Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.